trending Market Intelligence /marketintelligence/en/news-insights/trending/zhktucewl8JkNYH_t_2oRg2 content esgSubNav
In This List

Synlogic COO to step down

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Synlogic COO to step down

Synlogic Inc. said COO and head of corporate development, Andrew Gengos, will leave the company on Jan. 15, 2019.

The company, which agreed to a severance package with Gengos, said in a news release that his employment was "terminated without cause as a result of his role at the company being materially diminished."

Cambridge, Mass.-based Synlogic is a clinical-stage biopharmaceutical company that focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory and cancer diseases.